| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Hyperion DeFi, Inc.$2.42
0 (-0.21%)
Market Cap
54.87 M
EPS
-6.60
P/E Ratio
-
Value Trade
1.78 M
SEC Financials
Q1 2026Dilution Risk
Revenue
244.27 K
R&D Expenses
286.76 K
Operating CF
-4.20 M
Total Assets
70.07 M
Total Liabilities
11.57 M
Equity
58.49 M
D/E Ratio
12,345
2.55 %
Week
-13.19 %
1 Month
8.06 %
3 Month
-14.22 %
6 Month
-99.07 %
5 Year
-99.55 %
All Time
Cash Data
Cash Position
7.38 M
Monthly Burn
1.40 M
Runway
2.9 mo
Burn Trend
StableSEC Filing
May 15, 2026
Overview
Volume
274.13 K
52 Week Range
1.40 - 17.18
% held by Insiders
15.96 %
% held by Institutions
19.75 %
Enterprise Value
56.56 M
Total Shares
15.16 M
Short %
10.59 %
Float Shares
14.47 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Hyperion DeFi, Inc.
325Total events
2Upcoming
114Tier-1 (high impact)
2018 – 2027Coverage
Upcoming catalysts 2
TBD
T1FDA Approval
Subscribe to view catalyst details
TBD
T1FDA Approval
Subscribe to view catalyst details
Event history 2
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
TBD
◆Oral PresentationPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
low-dose atropine | pediatric progressive myopia | Phase 3 | 2024-11-15 | The rate of myopia progression was not significantly different between the two active treatment arms (0.01% and 0.1% atropine ophthalmic metered spray) and placebo. Read More | Eyenovia Provides Update on Phase 3 CHAPERONE Study A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint Company to discontinue study Read More | |
low-dose atropine | pediatric progressive myopia | Phase 3 | 2024-11-15 | The rate of myopia progression was not significantly different between the two active treatment arms (0.01% and 0.1% atropine ophthalmic metered spray) and placebo. Read More | Eyenovia Provides Update on Phase 3 CHAPERONE Study A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint Company to discontinue study Read More | |
low-dose atropine | pediatric progressive myopia | Phase 3 | 2024-11-15 | The rate of myopia progression was not significantly different between the two active treatment arms (0.01% and 0.1% atropine ophthalmic metered spray) and placebo. Read More | Eyenovia Provides Update on Phase 3 CHAPERONE Study A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint Company to discontinue study Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in HYPD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
HYPD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
HYPD▼ -0.2%today
Hyperion DeFi Schedules First Quarter Earnings Call for Wednesday, August 12 at 5:00 p.m. ET
Hyperion DeFi, Inc. has announced its earnings conference call for the second quarter ending June 30, 2026, scheduled for August 12, 2026, at 5:00 p.m. ET. The call will provide insights into the company's performance and future prospects. A press release detailing financial results will be issued prior to the call.
Read more →HYPDHyperion DeFi Enters Agreement with Skew Technologies to Launch HIP-3 Perpetual Futures Market and Listing Service
Hyperion DeFi has entered a partnership with Skew Technologies to deploy 500,000 HYPE tokens for a new suite of institutional perpetual futures products on Hyperliquid's HIP-3 markets. This agreement allows for the launch of custom markets and provides Hyperion with equity participation and revenue sharing. The collaboration aims to enhance market operations and expand trading product offerings.
Read more →HYPD▲ +7.5%on this news
Hyperion DeFi and Blockdaemon Partner to Expand Institutional Hyperliquid Staking Infrastructure
Hyperion DeFi has partnered with Blockdaemon to enhance its staking infrastructure for institutional clients on the Hyperliquid platform. This collaboration aims to meet the growing demand for reliable validator services and support institutional participation in decentralized finance. The partnership is a significant step towards scaling Hyperion's offerings and expanding its presence in the DeFi ecosystem.
Read more →HYPDHyperion DeFi Reiterates Guidance on Sunset of USDH and Felix Markets
Hyperion DeFi has reiterated its full-year guidance of $5 million to $7 million Adjusted Gross Profit despite the sunset of USDH and Felix Markets. The company plans to redeploy its HYPE tokens into more profitable strategies. CEO Hyunsu Jung emphasized the ongoing demand for their services and the commitment to innovation in the DeFi space.
Read more →HYPDHyperion DeFi Reports 1Q 2026 Financial Results with Record Net Income and Raises Guidance for Full Year 2026 Company Reports Record $8.8M Net Income and $19.5M Adjusted EBITDA (8) Treasury Exceeds 2.00M HYPE, 1.92M KNTQ
Hyperion DeFi reported robust financial results for Q1 2026, achieving a record net income of $8.8 million and an adjusted EBITDA of $19.5 million. The company's strategic 'Triple-Dip' deployment of HYPE tokens resulted in more than triple the income relative to traditional staking. CEO Hyunsu Jung emphasized the expanding opportunities presented by Hyperliquid and announced an increase in guidance for the full year 2026, as the company aims for break-even cash flows by year's end.
Read more →HYPDHyperion DeFi Announces Closing of Public Offering of Common Stock
Hyperion DeFi, Inc. has successfully closed a public offering of 2,777,778 shares of common stock, raising approximately $10 million. The shares were sold at $3.60 each, with the proceeds aimed at funding the company's HYPE treasury strategy and general corporate needs. The offering was underwritten by Chardan and supported by prominent investors.
Read more →HYPD▼ -22.1%on this newsshared move
Hyperion DeFi Announces Pricing of Public Offering of Common Stock
Hyperion DeFi, Inc. has announced the pricing of a public offering of 2,777,778 shares of common stock at $3.60 per share, aiming to raise around $10 million. The offering is set to close on May 7, 2026, pending customary conditions. Proceeds will be used for funding its treasury strategy and general corporate purposes.
Read more →HYPDHyperion DeFi Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Hyperion DeFi, Inc. has announced a proposed public offering of common stock and pre-funded warrants. The offering is subject to market conditions and aims to fund its treasury strategy and general corporate purposes. Chardan is acting as the sole underwriter, and there are no assurances regarding the timing or size of the offering.
Read more →HYPDHyperion DeFi Schedules First Quarter Earnings Call for Thursday, May 14 at 8:00 a.m. ET
Hyperion DeFi, Inc. has scheduled its first quarter earnings call for May 14, 2026, at 8:00 a.m. ET. The call will provide insights into the company's financial performance for the quarter ending March 31, 2026. A press release with detailed results will be issued prior to the call. Hyperion DeFi is recognized as the first publicly listed DeFi company in the U.S.
Read more →HYPD▲ +5.3%on this news
Hyperion DeFi Announces Participation in Upcoming Investor and Industry Conferences
Hyperion DeFi, Inc. announced its participation in several upcoming conferences, including the Digital Asset Yield Summit and Consensus Miami. The company aims to engage with investors and showcase its developments in the DeFi space. Additionally, Hyperion is working on the Optejet User Filled Device, enhancing treatment compliance for eye diseases.
Read more →HYPD▼ -5.7%on this news
Hyperion DeFi Reports 4Q and FY 2025 Financial Results with Quarter-over-Quarter Growth of +64% Revenue and +87% Adjusted Gross Profit
Hyperion DeFi, Inc. reported strong financial results for Q4 and FY 2025, with a 64% increase in revenue and an 87% rise in adjusted gross profit. The company's innovative 'Triple-Dip' strategy significantly boosted staking income. Despite these gains, Hyperion faced a net loss of $39.8 million in Q4 2025, highlighting ongoing challenges in the volatile market.
Read more →HYPDHyperion DeFi Enters HAUS Agreement with Silhouette
Hyperion DeFi has entered a HYPE Asset Use Service agreement with Silhouette, allowing users to benefit from reduced transaction fees on the Hyperliquid platform. This partnership aims to enhance trading efficiency while maintaining user privacy. Silhouette's architecture enables sophisticated trading strategies without compromising on execution. The collaboration is expected to drive growth and attract more users to the ecosystem.
Read more →HYPDHyperion DeFi Schedules Fourth Quarter and Full Year 2025 Earnings Call for Thursday, March 26 at 8:00 a.m. ET
Hyperion DeFi, Inc. has scheduled its earnings conference call for March 26, 2026, to discuss its fourth quarter and full year results for 2025. The company is focused on building a treasury of Hyperliquid's HYPE token and aims to provide streamlined access to its ecosystem. A press release with detailed results will precede the call.
Read more →HYPD▲ +9.3%on this news
Hyperion DeFi Announces Private Lending Pool Built by HyperLend
Hyperion DeFi has partnered with HyperLend to establish a permissioned lending pool using its HiHYPE token as collateral. This initiative aims to reduce borrowing costs from 8% to 4% while attracting institutional capital. The partnership is expected to enhance the DeFi ecosystem by providing a secure environment for on-chain credit strategies.
Read more →HYPD▼ -10.1%on this news
Hyperion DeFi Announces Institutional Volatility Income Vault Built on Rysk Protocol
Hyperion DeFi has partnered with Rysk to launch an institutional-grade yield-enhancement vault. This vault will utilize HYPE Liquid Staking Tokens and stablecoins for on-chain options strategies, aiming to generate additional yield. The initiative is designed to enhance institutional participation in the Hyperliquid ecosystem and optimize yield on HYPE holdings.
Read more →HYPD▲ +10.6%on this news
Hyperion DeFi Appoints Hyunsu Jung as Chief Executive Officer
Hyperion DeFi has appointed Hyunsu Jung as its new CEO, effective immediately. Jung, who previously served as Chief Investment Officer, aims to advance the company's strategic priorities for 2026. The leadership team has been further strengthened with the appointment of Robert Rubenstein as General Counsel. The company is focused on building a leading DeFi platform and enhancing its financial infrastructure.
Read more →HYPDHyperion DeFi Reports Third Quarter 2025 Financial Results with Record Net Income of $6.6 Million Management Initiates Q4'25 Adjusted Revenue (3) Guidance of 31% to 43% Q-o-Q Growth Over 13 Million HYPE Tokens Staked to
Hyperion DeFi, Inc. reported remarkable financial results for Q3 2025, achieving a record net income of $6.6 million. The company has also initiated optimistic guidance for Q4 2025, forecasting adjusted revenue growth of 31% to 43%. As of October 31, 2025, over 13 million HYPE tokens have been staked, reflecting strong engagement in its blockchain activities. The management anticipates that multiple business lines will generate positive operating cash flows starting in 2026, marking a significant corporate transformation for Hyperion DeFi.
Read more →HYPD▼ -11.9%on this news· ran to -28% by day 3shared move
Hyperion DeFi Announces Strategic Partnership with Felix to Launch HIP-3 Powered Perpetual Futures Market New Hyperliquid Product Compounds Yield on 500,000 HYPE Staked by the Company
Hyperion DeFi has announced a strategic partnership with Felix to launch a new perpetual futures market powered by the HIP-3 framework. The partnership allows Hyperion DeFi to provide 500,000 HYPE tokens to Felix, facilitating the management of this innovative market that expands the range of non-crypto assets available for trading. The initiative aims to create new revenue opportunities for Hyperion DeFi and enhance the overall ecosystem of decentralized finance. This venture is positioned to significantly increase Felix's total addressable market and drive growth in Hyperliquid's offerings.
Read more →HYPD▲ +7%on this news· ran to +24% by day 3
Hyperion DeFi Announces Appointment of David Knox as Chief Financial Officer PayPal's Former Head of Capital Markets and Head of Finance for Global Credit and Financial Services Joins Company Strong Advocate for Blockcha
Hyperion DeFi has appointed David Knox as Chief Financial Officer, effective immediately. Knox, who previously served as PayPal's Head of Capital Markets, will leverage his extensive experience to bolster Hyperion's decentralized finance strategy. His expertise is expected to facilitate the company's mission of enhancing institutional finance through blockchain technology. Alongside his appointment, Knox has been granted a stock incentive to align his interests with those of Hyperion DeFi and its shareholders.
Read more →HYPDHyperion DeFi Provides Corporate Update and Reports Second Quarter 2025 Financial Results Successfully establishes cryptocurrency treasury reserve focused on the HYPE token and becomes the first publicly listed U.S. comp
Hyperion DeFi, Inc. reported its second quarter 2025 financial results, highlighting significant advances in its DeFi strategies and the establishment of a treasury reserve for its HYPE token. The company has accumulated over 1.5 million HYPE tokens and is on track for FDA registration of the Optejet User Filled Device in September 2025. Despite reporting a net loss of $8.8 million in the quarter, management expressed optimism about future growth and continued market interest in their initiatives. Hyperion aims to provide innovative opportunities through its unique integration of decentralized finance.
Read more →HYPDEyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi, Inc. Name change reflects company's leadership position with its cryptocurrency treasury reserve strategy focused on the HYPE token Company to com
Eyenovia has announced a rebranding effort, changing its name to Hyperion DeFi, Inc. This decision highlights the company's new focus on a cryptocurrency treasury reserve strategy centered around the HYPE token. Shares will commence trading under the new ticker symbol 'HYPD' on July 3, 2025. In conjunction with this rebranding, the company has launched the Kinetiq x Hyperion validator to stake HYPE holdings and generate yield. The move is aimed at establishing leadership in the burgeoning decentralized finance (DeFi) market.
Read more →HYPDEyenovia Announces Co-Branded Validator with Kinetiq Kinetiq x Hyperion provides a premier liquid staking solution for institutional HYPE holders
Eyenovia has announced a strategic partnership with Kinetiq to launch a co-branded Hyperliquid validator aimed at enhancing liquid staking solutions for institutional holders of HYPE. This initiative represents a significant step in Eyenovia's engagement with the onchain economy and integrates their recent acquisition of over 1 million HYPE tokens. The validator's operation will be supported by Pier Two's robust infrastructure, providing stability and security to the network. The collaboration positions Eyenovia uniquely as a bridge between public markets and blockchain technology.
Read more →HYPDEyenovia Announces $50 Million Investment to Launch a Hyperliquid (HYPE token) Cryptocurrency Treasury Reserve Strategy
Eyenovia, Inc. has announced a $50 million investment to establish a treasury reserve strategy utilizing the HYPE cryptocurrency. This makes it the first U.S.-listed company to adopt such a strategy. The investment involves a securities purchase agreement with institutional investors, allowing Eyenovia to acquire over 1 million HYPE tokens. Alongside this, Hyunsu Jung has been appointed as Chief Investment Officer. The funding is set to enhance the company's blockchain presence, in addition to its ongoing work on its Optejet User Filled Device.
Read more →HYPDEyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results Eyenovia and Betaliq continue to negotiate a binding me
Eyenovia continues its negotiations for a potential merger with Betaliq while reporting its first quarter 2025 financial results. The company is on track to submit its Optejet User Filled Device for U.S. regulatory approval in September 2025. Notably, Eyenovia has reduced its cash burn by approximately 70% and restructured its debt, leading to improved financial conditions. The merger may create a new eyecare company with immediate revenue opportunities, while also developing solutions to enhance patient treatment experiences.
Read more →HYPDEyenovia Enters into Non-Binding Letter of Intent to effect Reverse Merger with Betaliq Combination, if successful, would be a new publicly-listed eye care company combining Betaliq's EyeSol water-free drug delivery tech
Eyenovia has entered a non-binding letter of intent for a reverse merger with Betaliq to create a new ophthalmic company. This merger would combine Eyenovia's Optejet dispensing platform with Betaliq's EyeSol drug delivery technology. Both companies aim to leverage their existing FDA-approved products and pipelines to enhance treatment options for glaucoma and other ocular diseases. The merger is contingent on due diligence, definitive agreements, board approvals, and necessary financing.
Read more →HYPDEyenovia Announces 1-for-80 Reverse Stock Split Reverse stock split, when effective, is intended to restore compliance with the Nasdaq minimum bid price requirement while Eyenovia continues to evaluate a broad range of s
Eyenovia, Inc. announced a 1-for-80 reverse stock split to comply with Nasdaq's minimum bid price requirement. This move will reduce the number of outstanding shares from approximately 167.5 million to about 2.1 million, effective January 31, 2025. The company's current market performance has prompted this strategic adjustment as it continues to evaluate various alternatives for growth. Despite the changes, Eyenovia maintains that this action will not affect stockholders' percentage interests in the company.
Read more →HYPDEyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering
Eyenovia, Inc. has announced a registered direct offering priced at $1.9 million, involving the sale of 20 million shares and associated warrants. The company plans to use the proceeds for general corporate purposes, including working capital and partial repayment of an existing loan. The offering is scheduled to close around December 9, 2024, subject to customary conditions. This move reflects Eyenovia's efforts to bolster its financial resources to support its product commercialization and development activities.
Read more →HYPDEyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering
Eyenovia, Inc. has announced a registered direct offering, pricing approximately 12.08 million shares and associated warrants for $1.3 million. The funds raised will primarily be utilized for working capital, including the advancement of their next generation Optejet device and commercialization of existing products. The offering is expected to close around November 26, 2024, pending regulatory approval and market conditions. The announcement comes as the company continues to navigate a competitive landscape in ophthalmic technology.
Read more →HYPDEyenovia Provides Update on Phase 3 CHAPERONE Study A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint Company to discontinue study
Eyenovia has announced that the Phase 3 CHAPERONE study, evaluating a treatment for pediatric progressive myopia, failed to meet its primary three-year efficacy endpoint as determined by an independent Data Review Committee. Consequently, the company plans to discontinue the study and conduct a thorough data review to assess next steps. All treatment dosages were reported as well-tolerated, but the lack of significant efficacy raises concerns about the future of the trial and the viability of the program. Eyenovia stated it would also consider strategic options to maximize stakeholder value amidst these disappointing results.
Read more →HYPDEyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of pediatric progressive myopia with preparations for interim analysis this
Eyenovia, Inc. reported its third quarter 2024 financial results, highlighting a successful U.S. launch of clobetasol propionate ophthalmic suspension and advancements in its MicroPine development for pediatric progressive myopia. The company commenced the production of registration batches for its Gen-2 Optejet device, which is expected to enhance its product offerings. Despite achieving significant milestones, Eyenovia also reported a net loss increase and higher operating expenses compared to the previous year.
Read more →HYPDEyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering
Eyenovia, Inc. has announced the pricing of a $4 million registered direct offering, set to close around September 30, 2024, pending customary conditions. The offering consists of 8,695,653 shares of common stock and warrants, with anticipated gross proceeds of approximately $4 million. The funds will be allocated for commercialization activities related to their products, completion of clinical studies, and potential repayment of existing debts.
Read more →HYPDEyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer Current CFO, John Gandolfo, to remain with the Company through November as part of planned retirement
Eyenovia, Inc. has appointed Andrew Jones as the new Chief Financial Officer, who brings over 30 years of experience in finance and accounting from the therapeutics and medical technology sectors. Current CFO John Gandolfo will assist with the transition through November as part of his planned retirement. Eyenovia is gearing up for significant milestones, including a crucial data readout for MicroPine and the launch of clobetasol, bolstering its growth prospects with already successful products in the market.
Read more →HYPDAugust 2024 Our Vision is to Improve Yours With topical ophthalmic therapies that are easier to use and easier to live with EYEN-COM-V2-0021 Forward-looking Statements Except for historical information, all the statement
Eyenovia's MydCombi ophthalmic spray has achieved FDA approval, allowing for effective pupil dilation with fewer side effects. The company plans to expand its sales outreach and has selected new offices to implement its innovative Optejet technology. This marks a significant advancement in ophthalmic treatments, particularly in pediatric myopia markets. However, the company must navigate safety concerns related to adverse reactions reported with its product.
Read more →HYPDEyenovia, Inc. Announces Proposed Public Offering
Eyenovia, Inc. announced plans for a proposed public offering of its common stock or pre-funded warrants to support its commercialization efforts and fund pivotal clinical studies. The proceeds from the offering will also be used for working capital and to repay existing debt. Market conditions will dictate the terms and completion of this offering, making it uncertain. Eyenovia is currently focusing on the commercialization of Mydcombi and clobetasol propionate while exploring strategic alternatives.
Read more →HYPDEyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update Following FDA consultation, announced plans for validation of the Gen-2 Optejet device and 2025 regulatory submission with Mydcombi as
Eyenovia, Inc. announced its second quarter 2024 financial results, revealing significant advancements in its product pipeline and ongoing sales efforts. The company is preparing for the validation of the Gen-2 Optejet device following an FDA consultation, with plans for a 2025 regulatory submission for its lead product, Mydcombi. Additionally, Eyenovia is advancing its Phase 3 CHAPERONE study for pediatric progressive myopia and has commenced sales activities for related products. However, the financial report indicated a notable increase in net loss and operating expenses compared to the previous year.
Read more →HYPDEyenovia Announces Pricing of $5M Registered Direct Offering
Eyenovia, Inc. has announced a $5 million registered direct offering, agreeing to sell 7,575,757 shares of common stock along with warrants. The combined offering price per share and warrant is set at $0.66, with the closing expected around July 1, 2024. Proceeds from the offering will be allocated to fund commercialization for Mydcombi and clobetasol propionate, as well as support a clinical study and working capital needs. This move highlights Eyenovia's ongoing commitment to expand its product offerings in the ophthalmic market.
Read more →HYPDJune 2024 We Are the Optejet Company Developing and commercializing ophthalmic therapeutics with Optecare services in large markets with high unmet needs EYEN - COM - V2 - 0021 Forward - looking Statements Except for his
Optejet Company is focused on developing and commercializing ophthalmic therapeutics through its Optecare services, addressing significant unmet needs in large markets. The recent FDA approval of MydCombi marks a transition to a commercial stage, highlighting the capabilities of their Optejet dispensing technology. The company anticipates a meeting with the FDA in Q3 2024 aimed at confirming the regulatory pathway for drug/device approval. With multiple products in the pipeline and a strong patent position, the potential for commercial success appears robust despite existing clinical and market uncertainties.
Read more →HYPDEyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol Remains on track towards accelerating devel
Eyenovia, Inc. reported its Q1 2024 financial results, revealing a net loss of approximately $10.9 million. The company is focused on accelerating the development of its pediatric progressive myopia treatment, alongside its two FDA-approved products, Mydcombi and clobetasol. Eyenovia aims for a significant sales growth over the next 18 months and is preparing for the launch of clobetasol in Q3 2024. Despite increased operating expenses, the company is optimistic about meeting critical developmental milestones and achieving profitability.
Read more →HYPDMarch 2024 We Are the Optejet® Company Developing and commercializing ophthalmic therapeutics with Optecare services in large markets with high unmet needs EYEN-COM-V2-0021 Forward-looking Statements Except for hist
Eyenovia is advancing its position in the ophthalmic therapeutics market with the Optejet device, which addresses chronic and acute dry eye and progressive myopia. The company is poised to launch critical products, including MydCombi and Clobetasol in 2024, targeting substantial addressable markets. The comprehensive financial snapshot highlights ongoing cash reserves and potential for growth, although they face challenges like the NDA hold for Apersure. Eyenovia's focus on enhancing ease of use and compliance positions them favorably within a sector characterized by high unmet needs.
Read more →HYPDJanuary 2024 We Are the Optejet Company Developing and commercializing ophthalmic drug - device therapeutics with Optecare services in large markets with high unmet needs EYEN - COM - V2 - 0021 Forward - looking Statemen
Eyenovia, known as the Optejet Company, is advancing its ophthalmic drug-device therapeutics and Optecare services, targeting large markets with significant unmet needs. The company is promoting its innovative Optejet delivery system, designed for ease of use and improved dosing precision compared to traditional eyedroppers. Forward-looking statements indicate optimism about market opportunities and product efficacy, but also acknowledge potential risks in clinical trials and regulatory processes. Eyenovia is positioning itself with a robust patent portfolio and a focus on enhancing patient compliance through digital technology.
Read more →HYPDEyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada MicroPine, currently in late phase III for pediatric progressive myopia, to complement Eyenovia's commercial-stage asset,
Eyenovia, Inc. has announced the re-acquisition of development and commercialization rights to MicroPine in the U.S. and Canada, aimed at treating pediatric progressive myopia. This move is part of a broader strategy to expedite the commercialization of advanced ophthalmic products using the Optejet delivery device. The market for treatments targeting myopia represents a substantial opportunity, estimated at nearly $2 billion annually. Eyenovia has expressed confidence in moving forward with the FDA to align on development strategies for this high-value program.
Read more →HYPDEyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update Acquired U.S. commercial rights to APP13007, currently under FDA review for post-surgical ocular pain and inflammation, from Formosa Phar
Eyenovia, Inc. reported its third quarter 2023 financial results, highlighting the acquisition of U.S. commercial rights to APP13007, which is currently under FDA review for post-surgical ocular pain and inflammation. The company announced the FDA's approval of Coastline International as a contract manufacturer for Mydcombi, with manufacturing for a broader launch expected to commence soon. Eyenovia's Chief Executive Officer, Michael Rowe, expressed optimism about the company's growth opportunities, including their strategic partnerships and development programs for the Optejet device. The net loss for the quarter was approximately $7.3 million, consistent with the previous year's performance.
Read more →HYPDSeptember 2023 EYEN-COM-V2-0012 1 Forward-looking Statements Except for historical information, all the statements, expectations and assumptions contained in this presentation are forward-looking statements. Forward-look
Eyenovia (HYPD) is advancing in the ophthalmic biotech sector with several pivotal developments. The company has executed valuable licensing agreements and maintains a robust intellectual property portfolio. Their leading product, MydCombi, has received FDA approval, validating their innovative Optejet technology. Additionally, Eyenovia is preparing for a national launch of APP13007, targeting various ocular conditions, indicating strong future growth potential.
Read more →HYPDEYENOVIA ANNOUNCES $12
Eyenovia, Inc. has announced a registered direct offering to raise $12 million through the sale of common stock and warrants. This funding will support the commercialization of a new post-ophthalmic surgery product, which is expected to receive regulatory approval by March 2024. Additionally, proceeds will be allocated for manufacturing automation of the Optejet device and general corporate purposes. The offering is set to close around August 29, 2023, pending customary conditions.
Read more →HYPDEyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals APP13007, if approved, may have an advantageous profile in dosing frequency and s
Eyenovia, Inc. has acquired the exclusive U.S. commercial rights to APP13007, an ophthalmic nanosuspension of clobetasol propionate, from Formosa Pharmaceuticals. If approved, APP13007 is expected to advantageously reduce dosing frequency and associated inflammation and pain after ocular surgeries. Eyenovia plans to leverage its existing sales force and intends to develop new formulations for dry eye treatment. The FDA review timeline includes a Prescription Drug User Fee Act (PDUFA) action date set for March 4, 2024, potentially positioning Eyenovia for new revenue streams in the ophthalmic market.
Read more →HYPDEyenovia Reports Second Quarter 2023 Financial Results and Provides Business Update Announced FDA approval of and first commercial sale of Mydcombi , the only fixed dose combination of tropicamide and phenylephrine for m
Eyenovia has reported its financial results for the second quarter of 2023, highlighting significant milestones such as the FDA approval and first commercial sale of Mydcombi. The company is advancing its Phase 3 Apersure presbyopia candidate with guidance from the FDA, indicating a clear path forward. However, Eyenovia recorded a net loss of approximately $(6.2) million and a reduction in cash reserves, raising concerns about its financial health moving forward.
Read more →HYPDAnnual Meeting 1 Forward-looking Statements Except for historical information, all the statements, expectations and assumptions contained in this presentation are forward-looking statements. Forward-looking statements in
Eyenovia is focusing on commercialization strategies for its ophthalmic products, including MydCombi and Apersure. The company has successfully met corporate objectives and received FDA approval for its Optejet technology. However, they face risks related to clinical trials and regulatory approvals that could impact their timelines and market acceptance. The potential market for targeted areas like glaucoma and dry eye is significant, indicating a promising future if hurdles can be navigated successfully.
Read more →HYPDEyenovia Reports First Quarter 2023 Financial Results and Provides Business Update Announced FDA approval of Mydcombi , a fixed dose combination of tropicamide and phenylephrine for mydriasis, the first FDA approved prod
Eyenovia, Inc. has reported its first quarter 2023 financial results, highlighting the FDA approval of Mydcombi, a new product that utilizes its Optejet delivery system. The company has received encouraging feedback from the FDA regarding its Microline presbyopia program, signaling a clear development pathway. Eyenovia is also working on expanding its ophthalmic product line through co-development agreements. However, the company recorded a net loss of $5.7 million, and its cash reserves have decreased, posing potential financial challenges ahead.
Read more →HYPDEyenovia Announces FDA Approval of Mydcombi , the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company's Proprietary Optejet Device Platform Represents the first FDA approved fixed-combination of tropic
Eyenovia, Inc. announced that the FDA has approved Mydcombi, a novel ophthalmic spray for inducing mydriasis, marking it as the first fixed-combination of tropicamide and phenylephrine for this purpose. This approval not only signifies a groundbreaking development in ophthalmic technology but also validates Eyenovia's proprietary Optejet device platform. The company plans to introduce Mydcombi to key offices in summer 2023, and is working on enhancing its manufacturing capabilities for future needs. Eyenovia sees significant opportunities to expand its platform technology into other ophthalmic conditions.
Read more →HYPDEyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update Announced FDA acceptance of Mydcombi New Drug Application (NDA) and PDUFA action date of
Eyenovia has reported its financial results for the fourth quarter of 2022, detailing a significant net loss compared to the same period last year. The company announced the FDA's acceptance of its New Drug Application for Mydcombi, with a PDUFA action date set for May 8, 2023. Positive FDA feedback was also received for its Microline program, which aims to treat presbyopia, outlining a clear path for development. Furthermore, a new co-development agreement with Formosa opens opportunities for pipeline expansion.
Read more →HYPDEyenovia Announces Independent Director Stephen Benjamin to Step Down to Assume Role of Head of White House's Office of Public Engagement
Eyenovia announces that Stephen Benjamin, an independent director, is stepping down from the Board to take on the role of Head of the White House's Office of Public Engagement. His tenure at Eyenovia started in February 2022, during which he provided valuable insights. The company is pleased with his new opportunity and will begin the search for a successor on the Board. Eyenovia continues to develop its innovative ophthalmic technologies amidst this change.
Read more →HYPDEyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals Collaboration will combine Eyenovia's Optejet dispensing technology with Formosa's APNT nanoparticle formulation platform for the potent
Eyenovia has announced a development collaboration agreement with Formosa Pharmaceuticals to integrate Eyenovia's Optejet dispensing technology with Formosa's APNT nanoparticle formulation platform. This partnership aims to advance the development of new topical ophthalmic therapeutics targeting significant unmet medical needs. Both companies will collaborate on testing these formulations and seek regulatory approvals through the FDA. Eyenovia anticipates that this collaboration will expand its development pipeline and open up new market opportunities.
Read more →HYPDMaking it Possible | February 2023 eyenovia.com 1 Except for historical information, all the statements, expectations and assumptions contained in this presentation are forward - looking statements. Forward - looking sta
Eyenovia is advancing its unique Optejet Microdose Array Print technology in the ophthalmic sector, with several product candidates in its late-stage pipeline. Key products like MydCombi and MicroPine are approaching FDA submission and have substantial market potential. The company's partnerships with established eyecare firms, such as Bausch+Lomb, are intended to support commercialization efforts. However, Eyenovia's forward-looking statements highlight inherent risks and uncertainties that could affect their performance and product development timelines.
Read more →HYPDEyenovia Announces FDA Acceptance of New Drug Application for MydCombi for In-Office Pupil Dilation Agency assigns PDUFA action date of
Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi for In-Office Pupil Dilation Agency assigns PDUFA action date of May 8, 2023 MydCombi , if approved, would be the first product incorporating Eyenovia's novel Optejet drug delivery technology Company als
Read more →HYPDEyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President Company also announces that Julia Haller, MD, is stepping down from its Board of Directors
Eyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President Company also announces that Julia Haller, MD, is stepping down from its Board of Directors NEW YORK-December 8, 2022-Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic t
Read more →HYPDEyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund Transaction proceeds, together with cash on-hand, expected to fund operations through late 2023/early 2024, including potential FDA approval of
Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund Transaction proceeds, together with cash on-hand, expected to fund operations through late 2023/early 2024, including potential FDA approval of MydCombi NEW YORK-November 29, 2022-Eyenovia, Inc. (NA
Read more →HYPDEyenovia Reports Third Quarter 2022 Financial Results and Provides Business Update Announced positive results from the second Phase 3 study of MicroLine in presbyopia, VISION-2; Company planning to meet with the FDA to g
Eyenovia Reports Third Quarter 2022 Financial Results and Provides Business Update Announced positive results from the second Phase 3 study of MicroLine in presbyopia, VISION-2; Company planning to meet with the FDA to gain alignment on regulatory path forward as a drug/devic
Read more →HYPDEyenovia Announces Positive Results from VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopia
Eyenovia Announces Positive Results from VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopia NEW YORK-October 20, 2022-Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet delivery system for us
Read more →HYPDEyenovia Announces Planned Retirement of Lead Independent Director Ken Lee, Jr.
Eyenovia Announces Planned Retirement of Lead Independent Director Ken Lee, Jr. NEW YORK- September 30, 2022-Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet delivery system for use both in combination with its own drug-devi
Read more →HYPDEyenovia Reports Second Quarter 2022 Financial Results Announced appointment of Michael Rowe as Chief Executive Officer and Board member Mydcombi NDA resubmission on track for the fourth quarter of 2022 Phase 3 VISION-2
Eyenovia Reports Second Quarter 2022 Financial Announced appointment of Michael Rowe as Chief Executive Officer and Board member Mydcombi NDA resubmission on track for the fourth quarter of 2022 Phase 3 VISION-2 study evaluating MicroLine as an on-demand treatment for impro
Read more →HYPDEyenovia Announces Appointment of Ophthalmic Industry Veteran Michael Rowe as Chief Executive Officer and Board Member Appointment of Mr. Rowe, Eyenovia's current Chief Operating Officer, maintains continuity while bring
Eyenovia Announces Appointment of Ophthalmic Industry Veteran Michael Rowe as Chief Executive Officer and Board Member Appointment of Mr. Rowe, Eyenovia's current Chief Operating Officer, maintains continuity while bringing significant ophthalmic industry, operations and comm
Read more →HYPDEyenovia Announces Appointments of Dr. Ellen Strahlman and Dr. Ram Palanki as New and Independent Members of its Board of Directors
Eyenovia Announces Appointments of Dr. Ellen Strahlman and Dr. Ram Palanki as New and Independent Members of its Board of Directors NEW YORK-July 7, 2022-Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdo
Read more →HYPDEyenovia Announces Planned Chief Executive Officer Transition CEO Dr. Sean Ianchulev will transition to non-executive Chairman of the Board
Eyenovia Announces Planned Chief Executive Officer CEO Dr. Sean Ianchulev will transition to non-executive Chairman of the Board YORK-June 7, 2022-Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose arra
Read more →HYPDEYENOVIA, INC. STOCK OWNERSHIP GUIDELINES Purpose The Board of Directors (" Board ") of Eyenovia, Inc. (the " Company ") believes that it is in the best interest of the Company and its shareholders to align the financial
STOCK OWNERSHIP GUIDELINES The Board of Directors ("Board") of Eyenovia, Inc. (the "Company") believes that it is in the best interest of the Company and its shareholders to align the financial interests of the non-employee members of the Board ("Outside Directors") with those
Read more →HYPDEyenovia Reports First Quarter 2022 Financial Results Mydcombi NDA resubmission on track for Q3 2022 Phase 3 VISION-2 study evaluating MicroLine as an on-demand treatment for improving near vision (presbyopia) progressin
Eyenovia Reports First Quarter 2022 Financial Mydcombi NDA resubmission on track for Q3 Phase 3 VISION-2 study evaluating MicroLine as an on-demand treatment for improving near vision (presbyopia) progressing as planned; topline data expected mid-year Ended Q1 with sufficient
Read more →HYPDMaking it Possible | April 2022 eyenovia.com 1 Except for historical information, all the statements, expectations and assumptions contained in this presentation are forward - looking statements. Forward - looking statem
Making it Possible | April 2022 eyenovia.com 1 Except for historical information, all the statements, expectations and assumptions contained in this presentation are forward - looking statements. Forward - looking statements include, but are not limited to, statements that expre
Read more →HYPDEyenovia Reports Fourth Quarter and Full Year 2021 Financial Results Successfully completed Type A meeting with FDA and anticipates MydCombi(tm) NDA resubmission in Q3 2022 Enrolled first patient in the Phase 3 VISION-2
Eyenovia Reports Fourth Quarter and Full Year 2021 Financial Results Successfully completed Type A meeting with FDA and anticipates MydCombi(tm) NDA resubmission in Q3 2022 Enrolled first patient in the Phase 3 VISION-2 study evaluating MicroLine as an on-demand treatment fo
Read more →HYPDEyenovia Strengthens Balance Sheet with a $15 Million Institutional Capital Investment from Armistice Capital Master Fund Ltd.
Eyenovia Strengthens Balance Sheet with a $15 Million Institutional Capital Investment from Armistice Capital Master Fund Ltd. YORK-March 4, 2022-Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP
Read more →HYPDEyenovia Concludes Type A Meeting with FDA Related to MydCombi NDA Resubmission No additional clinical work required; NDA resubmission anticipated in Q3 2022
Eyenovia Concludes Type A Meeting with FDA Related No additional clinical work required; NDA resubmission anticipated in Q3 2022 8, 2022-Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP ) therap
Read more →HYPDMaking it Possible | December 2021 eyenovia.com 1 Except for historical information, all the statements, expectations and assumptions contained in this presentation are forward - looking statements. Forward - looking sta
Making it Possible | December 2021 eyenovia.com 1 Except for historical information, all the statements, expectations and assumptions contained in this presentation are forward - looking statements. Forward - looking statements include, but are not limited to, statements that ex
Read more →HYPDEyenovia Reports Third Quarter 2021 Financial Results On track with VISION-2 phase 3 presbyopia trial and expedited resubmission of MydCombi New Drug Application as a drug/device combination in early 2022 Current cash re
Eyenovia Reports Third Quarter 2021 Financial On track with VISION-2 phase 3 presbyopia trial and expedited resubmission of MydCombi New Drug Application as a drug/device combination in early 2022 Current cash resources anticipated to be sufficient to cover MydCombi NDA resub
Read more →HYPDEyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopia Vision-2 follows successful Vision-1 trial with expected top-line results in Q2 2022 Presbyopia represents a multi-billion-d
Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopia Vision-2 follows successful Vision-1 trial with expected top-line results in Q2 2022 Presbyopia represents a multi-billion-dollar market opportunity in the U.S. alone NEW YORK, Nov. 04, 20
Read more →HYPDEyenovia Announces Reclassification of MydCombi(tm) as Drug-Device Combination Product by FDA Genus Medical Technologies, LLC v. FDA legal case leads to agency-wide review and reclassification of eye cups, eye droppers,
Eyenovia Announces Reclassification of MydCombi(tm) as Drug-Device Combination Product by FDA Genus Medical Technologies, LLC v. FDA legal case leads to agency-wide review and reclassification of eye cups, eye droppers, and ophthalmic dispensers Company received Complete Resp
Read more →HYPDEyenovia Reports Second Quarter 2021 Financial Results Announced positive topline data from its Phase 3 VISION-1 study evaluating MicroLine for the treatment of presbyopia Company on track to initiate second Phase 3 pres
Eyenovia Reports Second Quarter 2021 Financial Announced positive topline data from its Phase 3 VISION-1 study evaluating MicroLine for the treatment of presbyopia Company on track to initiate second Phase 3 presbyopia trial, VISION-2, by year-end 2021 MydCombi PDUFA date co
Read more →HYPDMaking it Possible June 2021 Except for historical information, all of the statements, expectations and assumptions contained in this presentation are for war d - looking statements. Forward - looking statements include,
Making it Possible June 2021 Except for historical information, all of the statements, expectations and assumptions contained in this presentation are for war d - looking statements. Forward - looking statements include, but are not limited to, statements that express our intent
Read more →HYPDEyenovia highlights Recent Progress in Three Phase 3 Programs, NDA Review Progress and Licensing Agreements Totaling up to $100 Million in Potential Pre-Commercial Revenue
Recent Progress in Three Phase 3 Programs, NDA Review Progress and Licensing Agreements Totaling up to $100 Million in Potential Pre-Commercial YORK-June 15, 2021-Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of micro
Read more →HYPDEyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical Study of MicroLine for the Treatment of Presbyopia Primary endpoint was achieved with well-tolerated micro-array print (MAP ) safety profile Upco
Eyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical Study of MicroLine for the Treatment of Presbyopia Primary endpoint was achieved with well-tolerated micro-array print (MAP ) safety profile Upcoming key 12 month milestones include Mydcombi PDUFA; VI
Read more →HYPDEyenovia Reports First Quarter 2021 Financial Results MydCombi PDUFA date confirmed for
Eyenovia Reports First Quarter 2021 Financial MydCombi PDUFA date confirmed for October 28, Completed patient enrollment in Phase 3 VISION-1 study evaluating MicroLine for the treatment of presbyopia; top-line data on track for Q2 Secures $25 million credit facility through
Read more →HYPDEyenovia Announces New $25 Million Credit Facility with Silicon Valley Bank
Announces New $25 Million Credit Facility with Silicon Valley Bank YORK-May 10, 2021-Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP ) therapeutics, today announced that the company has ent
Read more →HYPDMaking it Possible May 2021 Except for historical information, all of the statements, expectations and assumptions contained in this presentation are for war d - looking statements. Forward - looking statements include,
Making it Possible May 2021 Except for historical information, all of the statements, expectations and assumptions contained in this presentation are for war d - looking statements. Forward - looking statements include, but are not limited to, statements that express our intenti
Read more →HYPDEyenovia Announces Appointment of Renowned Ophthalmologist and Scientific Leader Dr. Julia Haller to its Board of Directors
Eyenovia Announces Appointment of Renowned Ophthalmologist Scientific Leader Dr. Julia Haller to its NEW YORK - April 1, 2021-Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose a
Read more →HYPDEyenovia Reports Fourth Quarter and Full Year 2020 Financial Results Announces MydCombi expected PDUFA date of
Eyenovia Reports Fourth Quarter and Full Year 2020 Financial Results Announces MydCombi expected PDUFA date of October Completes patient enrollment in Phase 3 VISION-1 study evaluating MicroLine for the treatment of presbyopia; topline data on track for Q2 Company to host co
Read more →HYPDMaking it Possible March 2021 Except for historical information, all of the statements, expectations and assumptions contained in this presentation are for war d - looking statements. Forward - looking statements include
Making it Possible March 2021 Except for historical information, all of the statements, expectations and assumptions contained in this presentation are for war d - looking statements. Forward - looking statements include, but are not limited to, statements that express our inten
Read more →HYPDEyenovia Announces FDA Acceptance of the MydCombi NDA PDUFA Date Expected 4Q 2021
Eyenovia Announces FDA Acceptance of PDUFA Date Expected 4Q 2021 NEW YORK- March 2, 2021-Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP ) therapeutics, today announced that the U.S. Food
Read more →HYPDEyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombi Targeting 80 Million Patient Encounters in the U.S. Annually
Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombi Targeting 80 Million Patient Encounters in the U.S. Annually NEW YORK-December 29, 2020-Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company with Phase 3 prog
Read more →HYPDMaking it Possible December 18, 2020
Making it Possible December 18, 2020 Except for historical information, all of the statements, expectations, and assumptions contained in this presentation are forward - looking statements . Forward - looking statements include, but are not limited to, statements that express ou
Read more →HYPDEyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia Topline Results Expected First Half of 2021
Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia Topline Results Expected First Half of NEW YORK-December 16, 2020-Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose a
Read more →HYPDEyenovia Announces FDA Acceptance of IND for MicroLine for Presbyopia, Clearing Path to Initiate Phase 3 VISION Trial by Year End
Announces FDA Acceptance of IND for MicroLine for Presbyopia, Clearing Path to Initiate Phase 3 VISION Trial by Year End YORK- December 3, 2020-- Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print
Read more →HYPDMaking it Possible December 2020 Except for historical information, all of the statements, expectations, and assumptions contained in this presentation are forward - looking statements . Forward - looking statements incl
Making it Possible December 2020 Except for historical information, all of the statements, expectations, and assumptions contained in this presentation are forward - looking statements . Forward - looking statements include, but are not limited to, statements that express our in
Read more →HYPDEyenovia Reports Third Quarter 2020 Financial Results Company to host conference call and webcast today, November 10, at 4:30pm ET New York, NY
Eyenovia Reports Third Quarter 2020 Financial Company to host conference call and webcast today, November 10, at 4:30pm ET New York, NY, Nov. 10, 2020 - Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose ar
Read more →HYPDEyenovia Investor Contacts: John Gandolfo jgandolfo@eyenovia.com (917) 289-1117 Eric Ribner LifeSci Advisors, LLC eric@lifesciadvisors.com (646) 751-4363 Eyenovia Media Contact: Diana Soltesz Pazanga Health Communication
health LICENSES EYENOVIA'S INVESTIGATIONAL TREATMENT FOR THE REDUCTION OF PEDIATRIC MYOPIA PROGRESSION IN CHILDREN ages 3-12 LAVAL, QC and NEW YORK, Oct. 12, 2020 - Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), Bausch + Lomb, its leading global eye health busi
Read more →HYPDEyenovia, Inc. Announces Proposed Public Offering of Common Stock
Eyenovia, Inc. Announces Proposed Public Offering of Common Stock NEW YORK, Aug. 18, 2020 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP ) therapeutics, today announced that it intend
Read more →HYPDEyenovia Reports Second Quarter 2020 Financial Results New York, NY
Eyenovia Reports Second Quarter 2020 New York, NY - August 12, 2020 - Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP ) therapeutics, today reported its financial results for the second qu
Read more →HYPDEyenovia and Arctic Vision Announce Exclusive Collaboration and License Agreement to Develop and Commercialize MicroPine and MicroLine in Greater China and South Korea Eyenovia Eligible to Receive up to a Total of $45.75
Eyenovia and Arctic Vision Announce Exclusive Collaboration and License Agreement to Develop and Commercialize MicroPine and MicroLine in Greater China and South Korea Eyenovia Eligible to Receive up to a Total of $45.75 million in Upfront Payments and Development and Commerci
Read more →HYPDEyenovia Resumes Recruitment of Phase III CHAPERONE Study for Progressive Myopia New York, NY
Eyenovia Resumes Recruitment of Phase III CHAPERONE Study for Progressive Myopia New York, NY - June 30, 2020 - Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP ) therapeutics, today annou
Read more →HYPDEyenovia Reports First Quarter 2020 Financial Results New York, NY
Eyenovia Reports First Quarter 2020 Financial New York, NY - May 13, 2020 - Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announ
Read more →HYPDEyenovia Reports Fourth Quarter and Full Year 2019 Financial Results New York, NY
Eyenovia Reports Fourth Quarter and Full Year 2019 Financial Results New York, NY - March 25, 2020 -Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery
Read more →HYPDEyenovia, Inc. Announces Approximately $6.0 Million Private Placement New York, NY
Eyenovia, Inc. Announces Approximately $6.0 Million Private Placement New York, NY -- March 23, 2020 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print tech
Read more →HYPDMaking it Possible November 2019 Except for historical information, all of the statements, expectations, and assumptions contained in this presentation are forward - looking statements . Forward - looking statements incl
Making it Possible November 2019 Except for historical information, all of the statements, expectations, and assumptions contained in this presentation are forward - looking statements . Forward - looking statements include, but are not limited to, statements that express our in
Read more →HYPDEyenovia Reports Third Quarter 2019 Financial Results New York, NY
Eyenovia Reports Third Quarter 2019 Financial New York, NY - November 13, 2019 - Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today a
Read more →HYPDEyenovia Advances MicroLine for the Treatment of Presbyopia Towards Phase III Development and Reprioritizes Late-Stage Ophthalmology Pipeline Defers development activities of MicroProst and MicroTears Company to host con
Eyenovia Advances MicroLine for the Treatment of Presbyopia Towards Phase III Development and Reprioritizes Late-Stage Ophthalmology Pipeline Defers development activities of MicroProst Company to host conference call on Tuesday, October 29, 2019 at 5:00 pm ET New York, NY -
Read more →HYPDEyenovia Reports Second Quarter 2019 Financial Results New York, NY
Eyenovia Reports Second Quarter 2019 New York, NY - August 12, 2019 - Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced it
Read more →HYPDEyenovia Enrolls First Patient in Phase III CHAPERONE Study for Progressive Myopia Program Follows Successful Completion of Phase III Program in Mydriasis New York, NY
Eyenovia Enrolls First Patient in Phase III CHAPERONE Study for Progressive Myopia Program Follows Successful Completion of Phase III Program in Mydriasis New York, NY - June 4, 2019 - Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company devel
Read more →HYPDEyenovia Reports First Quarter 2019 Financial Results New York, NY
Eyenovia Reports First Quarter 2019 Financial New York, NY - May 14, 2019 - Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announ
Read more →HYPDEyenovia Reports Fourth Quarter and Full Year 2018 Financial Results New York, NY
Eyenovia Reports Fourth Quarter and Full Year 2018 Financial Results New York, NY - March 27, 2019 - Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print deliver
Read more →HYPDMaking it Possible Analyst & Investor Lunch February 27, 2019
Making it Possible Analyst & Investor Lunch February 27, 2019 Agenda 1. Brief overview of Eyenovia 2. Recent updates and accomplishments 3. Micro Stat MIST - 1 and MIST - 2 results 4. Discussion on in - office efficiency with Micro Stat with Robert Stapper, Director of Research
Read more →HYPDEyenovia Announces Confirmatory Results from Second MicroStat Phase III Registration Study for Mydriasis MIST-2 study meets primary endpoint First-in-class fixed combination mydriatic agent demonstrated robust efficacy,
Eyenovia Announces Confirmatory Results from Second MicroStat Phase III Registration Study for Mydriasis MIST-2 study meets primary endpoint First-in-class fixed combination mydriatic agent demonstrated robust efficacy, good tolerability in confirmatory MIST-2 Study NEW YORK
Read more →HYPDEyenovia confirms expanded MicroProst Phase III indication to enroll broad patient population for IOP lowering Expanded, more efficient development aimed at maximizing MicroProst's program value New York, NY
Eyenovia confirms expanded MicroProst Phase III indication to enroll broad patient population for IOP lowering Expanded, more efficient development aimed at maximizing MicroProst's program value New York, NY - February 13, 2019 - Eyenovia, Inc. (NASDAQ: EYEN), a clinical sta
Read more →HYPDEyenovia Announces FDA Acceptance of IND Application for MicroPine to Reduce the Progression of Myopia On track to initiate Phase III trial in H1 2019 New York, NY
Eyenovia Announces FDA Acceptance of IND Application for MicroPine to Reduce the Progression of Myopia On track to initiate Phase III trial New York, NY - February 6, 2019 - Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pip
Read more →HYPDEyenovia Announces Positive Results in the MicroStat MIST-1 Phase III Registration Study for Mydriasis MIST-1 study met primary endpoint First-in-class fixed combination mydriatic agent demonstrated robust efficacy, high
Eyenovia Announces Positive Results in the MicroStat MIST-1 Phase III Registration Study for Mydriasis MIST-1 study met primary endpoint First-in-class fixed combination mydriatic agent demonstrated robust efficacy, high tolerability; Study further validates OpteJet platform
Read more →HYPDEyenovia Prices Public Offering of Common Stock NEW YORK, New York
Eyenovia Prices Public Offering of Common NEW YORK, New York - December 19, 2018 - Eyenovia, Inc. ("Eyenovia" or the "Company") (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-pr
Read more →HYPDEyenovia Completes Patient Enrollment in MicroStat MIST-1 Study and Enrolls First Patient in MIST-2 Study Topline results for the Phase III MicroStat Program for pharmacologic mydriasis expected H1 2019 New York, NY
Eyenovia Completes Patient Enrollment in MicroStat MIST-1 Study and Enrolls First Patient in MIST-2 Study Topline results for the Phase III MicroStat Program for pharmacologic mydriasis expected H1 2019 New York, NY - December 3, 2018 - Eyenovia, Inc. (NASDAQ: EYEN) today an
Read more →HYPDEyenovia Initiates Phase III MicroStat Program for Pharmacologic Mydriasis: Enrolls First Patient in MIST-1 Study Topline results for Phase III MicroStat program expected H1 2019 New York, NY
Eyenovia Initiates Phase III MicroStat Program for Pharmacologic Mydriasis: Enrolls First Patient in MIST-1 Study Topline results for Phase III MicroStat program expected H1 2019 New York, NY - November 26, 2018 - Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic bi
Read more →HYPDEyenovia Reports Third Quarter 2018 Financial Results New York, NY
Eyenovia Reports Third Quarter 2018 Financial New York, NY - November 13, 2018 - Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed medications topically
Read more →HYPDEyenovia Reports Second Quarter 2018 Financial Results New York, NY
Reports Second Quarter 2018 Financial Results New York, NY - August 14, 2018 - Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed medications topically t
Read more →HYPDEyenovia's EYN PG21 Trial Evaluating High-Precision Microdose of Latanoprost Demonstrates Robust Intraocular Pressure Lowering and Patient Usability Positive results validate Eyenovia's piezo-print technology for topical
Eyenovia's EYN PG21 Trial Evaluating High-Precision Microdose of Latanoprost Demonstrates Robust Intraocular Pressure Lowering and Patient Usability Positive results validate Eyenovia's piezo-print technology for topical eye treatment as Company prepares for Phase III trials i
Read more →HYPDEyenovia Reports First Quarter 2018 Financial Results and Completion of EYN PG21 Study New York, NY
Eyenovia Reports First Quarter 2018 Financial Results and Completion of EYN PG21 Study New York, NY - May 9, 2018 - Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print tec
Read more →HYPDEyenovia Announces Fourth Quarter and Full Year 2017 Financial Results Successfully Completed EYN PG21 Study Evaluating Usability and IOP Lowering with Micro-Therapeutic Latanoprost New York, NY
Eyenovia Announces Fourth Quarter and Full Year 2017 Financial Results Successfully Completed EYN PG21 Study Evaluating Usability and IOP Lowering with Micro-Therapeutic Latanoprost New York, NY - April 2, 2018 - Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage biopharmaceuti
Read more →HYPDEyenovia Appoints Three Industry Veterans to Board of Directors New York, NY
Eyenovia Appoints Three Industry Veterans to Board of Directors New York, NY - March 26, 2018 - Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver m
Read more →HYPDEyenovia Announces Pricing of Initial Public Offering New York, NY
Eyenovia Announces Pricing of Initial New York, NY - January 25, 2018 - Eyenovia Inc. ("Eyenovia"), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically
Read more →Competitive Position
How HYPD ranks across every disease it competes inCompetitive Position is a premium feature
See how HYPD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial